{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:16:20Z","timestamp":1777907780989,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Pharmacopsychiatry"],"abstract":"<jats:p>Tranquilizers and antidepressants were investigated for their effect on the\nglycogen phosphorylase of rat brain. In general, the tranquilizers depressed and the antidepressants\nenhanced the phosphorylase activity. A unified explanation for the effect of\nmost of both tranquilizers and antidepressants on the phosphorylase activity is given, based\non a reasonable mode of action and a postulate stating that the phosphorylase activity is\ncorrelated with the availability of noreprinephrine at the adrenergic receptor sites. These\nfacts suggest that the phosphorylase activity of brain may be a barometer for CNS adrenergic\nactivity. From the nature of drugs involved one could say that depression (an affective\nstate) is associated with decreased phosphorylase activity and excitement or relief from\ndepression with enhancement of the activity, either from the normal or the reduced state.<\/jats:p>","DOI":"10.1159\/000468259","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:20:13Z","timestamp":1502472013000},"page":"98-110","source":"Crossref","is-referenced-by-count":2,"title":["Possible Involvement of Glycogen Phosphorylase of Brain\nin the Affective States"],"prefix":"10.1159","author":[{"given":"T.T.","family":"Iriye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.A.","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["International Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000468259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:47:13Z","timestamp":1777643233000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000468259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000468259","archive":["Portico"],"relation":{},"ISSN":["0020-8272","2504-2580"],"issn-type":[{"value":"0020-8272","type":"print"},{"value":"2504-2580","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}